|
1
|
Chan JK, Teoh D, Hu JM, Shin JY, Osann K
and Kapp DS: Do clear cell ovarian carcinomas have poorer prognosis
compared to other epithelial cell types? A study of 1411 clear cell
ovarian cancers. Gynecol Oncol. 109:370–376. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sugiyama T, Kamura T, Kigawa J, Terakawa
N, Kikuchi Y, Kita T, Suzuki M, Sato I and Taguchi K: Clinical
characteristics of clear cell carcinoma of the ovary: A distinct
histologic type with poor prognosis and resistance to
platinum-based chemotherapy. Cancer. 88:2584–2589. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Itamochi H, Kigawa J and Terakawa N:
Mechanisms of chemoresistance and poor prognosis in ovarian clear
cell carcinoma. Cancer Sci. 99:653–658. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Takano M, Kikuchi Y, Yaegashi N, Kuzuya K,
Ueki M, Tsuda H, Suzuki M, Kigawa J, Takeuchi S, Tsuda H, et al:
Clear cell carcinoma of the ovary: A retrospective muticentre
experience of 254 patients with complete surgical staging. Br J
Cancer. 94:1369–1374. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gross AL, Kurman RJ, Vang R, Shih IeM and
Visvanathan K: Precursor lesions of high-grade serous ovarian
carcinoma: Morphological and molecular characteristics. J Oncol.
2010:1262952010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kurman RJ and Shih IeM: The origin and
pathogenesis of epithelial ovarian cancer: A proposed unifying
theory. Am J Surg Pathol. 34:433–443. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tan DS and Kaye S: Ovarian clear cell
adenocarcinoma: A continuing enigma. J Clin Pathol. 60:355–360.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wiegand KC, Shah SP, AlAgha OM, Zhao Y,
Tse K, Zeng T, Senz J, McConechy MK, Anglesio MS, Kalloger SE, et
al: ARID1A mutations in endometriosis-assciated ovarian carcinoma.
N Engl J Med. 363:1532–1543. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jones S, Wang TL, Shih IeM, Mao TL,
Nakayama K, Roden R, Glas R, Slamon D, Diaz LA Jr, Vogelstein B, et
al: Frequent mutations of chromatin remodeling gene ARID1A in
ovarian clear cell carcinoma. Science. 330:228–231. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yamamoto S, Tsuda H, Takano M, Tamai S and
Matsubara O: PIK3CA mutaitons and loss of ARID1A protein expression
are early events in the development of cystic ovarian clear cell
adenocarcinoma. Virchows Arch. 460:77–87. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tan DS, Iravani M, McCluggage WG, Lambros
MB, Milanezi F, Mackay A, Gourley C, Geyer FC, Vatcheva R, Millar
J, et al: Genomic analysis reveals the molecular heterogeneity of
ovarian clear cell carcinomas. Clin Cancer Res. 17:1521–1534. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yamamoto S, Tsuda H, Yoshikawa T, Kudoh K,
Kita T, Furuya K, Tamai S and Matsubara O: Clear cell
adenocarcinoma associated with clear cell adenofibromatous
components: A subgroup of ovarian clear cell adenocarcinoma with
distinct clinicopathologic characteristics. Am J Surg Pathol.
31:999–1006. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Veras E, Mao TL, Ayhan A, Ueda S, Lai H,
Hayran M, Shih IeM and Kurman RJ: Cystic and adenofibromatous clear
cell carcinomas of the ovary: Distinctive tumors that differ in
their pathogenesis and behavior: A clinicopathologic analysis of
122 cases. Am J Surg Pathol. 33:844–853. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Katagiri A, Nakayama K, Rahman MT, Rahman
M, Katagiri H, Nakayama N, Ishikawa M, Ishibashi T, Iida K,
Kobayashi H, et al: Loss of ARID1A expression is related to shorter
progression-free survival and chemoresistance in ovarian clear cell
carcinoma. Mod Pathol. 25:282–288. 2012.PubMed/NCBI
|
|
15
|
Yokoyama Y, Matsushita Y, Shigeto T,
Futagami M and Mizunuma H: Decreased ARID1A is correlated with
chemoresistance in epithelial ovarian cancer. J Gynecol Oncol.
25:58–63. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Maeda D, Mao TL, Fukuyamaa M, Nakagawa S,
Yano T, Taketani Y and Shih IeM: Clinicopathological significance
of loss of ARID1A immunoreactivity in ovarian clear cell carcinoma.
Int J Mol Sci. 11:5120–5128. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lowery WJ, Schildkraut JM, Akushevich L,
Bentley R, Marks JR, Huntsman D and Berchuck A: Loss of
ARID1A-associated protein expression is a frequent event in clear
cell and endometrioid ovarian cancers. Int J Gynecol Cancer.
22:9–14. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kato M, Yamamoto S, Takano M, Matsubara O
and Furuya K: Aberrant expression of mammalian target of rapamycin,
hypoxia-inducible factor-1α and glucose transporter 1 in the
development of ovarian clear-cell adenocarcinoma. Int J Gynecol
Pathol. 31:254–263. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Samartzis EP, Samartzis N, Noske A, Fedier
A, Caduff R, Dedes KJ, Fink D and Imesch P: Loss of
ARID1A/BAF250a-expression in endometriosis: A biomarker for risk of
carcinogenic transformation? Mod Pathol. 25:885–892. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xiao W, Awadallah A and Xin W: Loss of
ARID1A/BAF250a expression in ovarian endometriosis and clear cell
carcinoma. Int J Clin Exp Pathol. 5:642–650. 2012.PubMed/NCBI
|
|
21
|
Ayhan A, Mao TL, Seckin T, Wu CH, Guan B,
Ogawa H, Futagami M, Mizukami H, Yokoyama Y, Kurman RJ and Shih
IeM: Loss of ARID1A expression is an early molecular event in tumor
progression from ovarian endometriotic cyst to clear cell and
endometrioid carcinoma. Int J Gynecol Cancer. 22:1310–1315. 2012.
View Article : Google Scholar : PubMed/NCBI
|
